Larimar Therapeutics to Participate in Upcoming Investor Conferences Read more about Larimar Therapeutics to Participate in Upcoming Investor Conferences Larimar Therapeutics Reports Third Quarter 2020 Operating and Financial Results Read more about Larimar Therapeutics Reports Third Quarter 2020 Operating and Financial Results Larimar Therapeutics Announces Formation of Scientific Advisory Board Read more about Larimar Therapeutics Announces Formation of Scientific Advisory Board Larimar Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Read more about Larimar Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Larimar Therapeutics to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference Read more about Larimar Therapeutics to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference Larimar Therapeutics Reports Second Quarter 2020 Operating and Financial Results Read more about Larimar Therapeutics Reports Second Quarter 2020 Operating and Financial Results Larimar Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference Read more about Larimar Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference Larimar Therapeutics Announces Positive Opinion on Orphan Drug Designation Received from the European Medicines Agency for CTI-1601 for the Treatment of Friedreich’s Ataxia Read more about Larimar Therapeutics Announces Positive Opinion on Orphan Drug Designation Received from the European Medicines Agency for CTI-1601 for the Treatment of Friedreich’s Ataxia Larimar Therapeutics Announces Dosing of Patients in Third Cohort of Phase 1 SAD Trial of CTI-1601 for Treatment of Friedreich’s Ataxia Read more about Larimar Therapeutics Announces Dosing of Patients in Third Cohort of Phase 1 SAD Trial of CTI-1601 for Treatment of Friedreich’s Ataxia Jonathan Leff Chair of the Nominating and Governance CommitteeMember of the Compensation Committee Charter Jonathan Leff Pagination First page « First Previous page ‹ Previous … Page 3 Page 4 Page 5 Page 6 Current page 7 Page 8 Page 9 Page 10 Page 11 … Next page Next › Last page Last » Subscribe to
Larimar Therapeutics to Participate in Upcoming Investor Conferences Read more about Larimar Therapeutics to Participate in Upcoming Investor Conferences
Larimar Therapeutics Reports Third Quarter 2020 Operating and Financial Results Read more about Larimar Therapeutics Reports Third Quarter 2020 Operating and Financial Results
Larimar Therapeutics Announces Formation of Scientific Advisory Board Read more about Larimar Therapeutics Announces Formation of Scientific Advisory Board
Larimar Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Read more about Larimar Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Larimar Therapeutics to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference Read more about Larimar Therapeutics to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference
Larimar Therapeutics Reports Second Quarter 2020 Operating and Financial Results Read more about Larimar Therapeutics Reports Second Quarter 2020 Operating and Financial Results
Larimar Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference Read more about Larimar Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference
Larimar Therapeutics Announces Positive Opinion on Orphan Drug Designation Received from the European Medicines Agency for CTI-1601 for the Treatment of Friedreich’s Ataxia Read more about Larimar Therapeutics Announces Positive Opinion on Orphan Drug Designation Received from the European Medicines Agency for CTI-1601 for the Treatment of Friedreich’s Ataxia
Larimar Therapeutics Announces Dosing of Patients in Third Cohort of Phase 1 SAD Trial of CTI-1601 for Treatment of Friedreich’s Ataxia Read more about Larimar Therapeutics Announces Dosing of Patients in Third Cohort of Phase 1 SAD Trial of CTI-1601 for Treatment of Friedreich’s Ataxia
Jonathan Leff Chair of the Nominating and Governance CommitteeMember of the Compensation Committee Charter Jonathan Leff